Kenvue Inc. (NYSE:KVUE) Shares Purchased by Advisors Asset Management Inc.

Advisors Asset Management Inc. boosted its stake in Kenvue Inc. (NYSE:KVUE) by 8.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,371 shares of the company’s stock after acquiring an additional 1,559 shares during the period. Advisors Asset Management Inc.’s holdings in Kenvue were worth $471,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. SVB Wealth LLC raised its holdings in shares of Kenvue by 7.3% during the first quarter. SVB Wealth LLC now owns 14,042 shares of the company’s stock worth $301,000 after purchasing an additional 952 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Kenvue by 53.7% during the first quarter. Janus Henderson Group PLC now owns 165,162 shares of the company’s stock worth $3,541,000 after purchasing an additional 57,679 shares during the period. Tidal Investments LLC raised its holdings in shares of Kenvue by 47.5% during the first quarter. Tidal Investments LLC now owns 131,764 shares of the company’s stock worth $2,828,000 after purchasing an additional 42,418 shares during the period. Comerica Bank raised its holdings in shares of Kenvue by 8.6% during the first quarter. Comerica Bank now owns 699,045 shares of the company’s stock worth $15,002,000 after purchasing an additional 55,179 shares during the period. Finally, Advisory Resource Group acquired a new stake in shares of Kenvue during the first quarter worth $287,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE:KVUE opened at $24.12 on Thursday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average of $22.89 and a 200-day moving average of $20.94. The firm has a market cap of $46.24 billion, a price-to-earnings ratio of 43.85, a price-to-earnings-growth ratio of 2.20 and a beta of 1.36.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same quarter last year, the firm posted $0.31 EPS. The business’s revenue for the quarter was down .4% on a year-over-year basis. Analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. UBS Group increased their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.